Description: Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. It engages in drug discovery and development of new chemical entities (NCE) in central nervous system therapies. The company's product candidates include SUVN-502, which is in Phase II clinical trials for the treatment of Alzheimer's disease; SUVN-G3031, a potent and selective histamine H3 receptor inverse agonist, which has completed Phase I trials for the treatment of sleep and cognitive disorders; SUVN-D4010, a potent, selective, and orally bio-available and brain penetrant 5-HT4 receptor partial agonist, which has completed Phase I trials for the treatment of major depressive disorders; and SUVN-911, a novel, potent, and selective a4ß2 nicotinic acetylcholine receptor antagonist, which has completed Phase I trials for the treatment of depressive disorders. It is also developing SUVN-I6107 for the treatment of cognitive disorders, SUVN-M8036 for the treatment of psychiatric disorders, SUVN-D1044 for the treatment of gastrointestinal disorders, P2X7 Antagonist for the treatment of pain and inflammation, M4 PAM for the treatment of Psychosis, and 5-HT1A Partial Agonist for the treatment of resistant depression. The company was formerly known as Suven Pharmaceuticals Pvt. Ltd. and changed its name to Suven Life Sciences Limited in 2003. The company was founded in 1989 and is headquartered in Hyderabad, India. Suven Life Sciences Limited is a subsidiary of Jasti Property and Equity Holdings Private Limited.
Home Page: www.suven.com
# 8-2-334, SDE Serene Chambers
Hyderabad,
500034
India
Phone:
91 40 2354 1142
Officers
| Name | Title |
|---|---|
| Mr. Venkateswarlu Jasti | Exec. Chairman & CEO |
| Ms. Sudharani Jasti | Whole-Time Director |
| Mr. M. Mohan Kumar | Chief Financial Officer |
| Mr. Shrenik Soni | Company Sec. & Compliance Officer |
| Ms. Kalyani Jasti | Pres of US Operations |
Exchange: BSE
Country: IN
Currency: Indian Rupee (INR)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 24.2315 |
| Price-to-Sales TTM: | 56.0311 |
| IPO Date: | |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |